ALLERGAN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?
ALLERGAN has seventy-three approved drugs.
There are nine US patents protecting ALLERGAN drugs.
There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and sixteen supplementary protection certificates in eighteen countries.
Summary for ALLERGAN
International Patents: | 181 |
US Patents: | 9 |
Tradenames: | 70 |
Ingredients: | 54 |
NDAs: | 73 |
Patent Litigation for ALLERGAN: | See patent lawsuits for ALLERGAN |
PTAB Cases with ALLERGAN as patent owner: | See PTAB cases with ALLERGAN as patent owner |
Drugs and US Patents for ALLERGAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-002 | Jun 13, 1997 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Allergan | PROPINE | dipivefrin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 018239-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Allergan | TRETINOIN | tretinoin | CREAM;TOPICAL | 090098-001 | Mar 22, 2010 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Allergan | BYSTOLIC | nebivolol hydrochloride | TABLET;ORAL | 021742-003 | Dec 17, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Allergan | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-011 | Jul 9, 2012 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALLERGAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | 5,760,485 | ⤷ Try a Trial |
Allergan | CRINONE | progesterone | GEL;VAGINAL | 020701-001 | Jul 31, 1997 | 5,543,150 | ⤷ Try a Trial |
Allergan | PROPINE | dipivefrin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 018239-001 | Approved Prior to Jan 1, 1982 | 3,839,584 | ⤷ Try a Trial |
Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | 4,980,470*PED | ⤷ Try a Trial |
Allergan | OCUFLOX | ofloxacin | SOLUTION/DROPS;OPHTHALMIC | 019921-001 | Jul 30, 1993 | 4,551,456*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Sublingual Tablets | 5 mg and 10 mg | ➤ Subscribe | 2013-08-13 |
➤ Subscribe | Extended-release Capsules | 60 mg | ➤ Subscribe | 2009-03-02 |
➤ Subscribe | Transdermal System Extended-re | 3.9 mg/24 hrs | ➤ Subscribe | 2008-08-19 |
➤ Subscribe | Ophthalmic Solution | 0.30% | ➤ Subscribe | 2007-07-19 |
➤ Subscribe | Tablets | 2.5 mg, 5 mg, 10 mg, and 20 mg | ➤ Subscribe | 2011-12-19 |
➤ Subscribe | Sublingual Tablets | 2.5 mg | ➤ Subscribe | 2017-07-27 |
➤ Subscribe | Capsules | 4 mg and 8 mg | ➤ Subscribe | 2012-10-09 |
International Patents for ALLERGAN Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Croatia | P20030034 | ⤷ Try a Trial |
Estonia | 200300046 | ⤷ Try a Trial |
Norway | 20030494 | ⤷ Try a Trial |
Mexico | 361020 | ⤷ Try a Trial |
Cyprus | 1111061 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALLERGAN Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1304992 | 92401 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
0746317 | 10C0056 | France | ⤷ Try a Trial | PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901 |
0617614 | SPC/GB01/014 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018 |
0600675 | 1090028-0.L | Sweden | ⤷ Try a Trial | PRODUCT NAME: SILODOSIN ELLER FARMACEUTISKA GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/09/607/001-014 " EESGODKLANDKOD="EG" EESGODKDATUM="2010-01-29" SEGODKNR="EU/1/09/607/001-014 " SEGODKLANDKOD="EG" SEGODKDATUM="2010-01-29" FLAG="L" SPCNR="1090028-0" 20100129 |
1480644 | 93338 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: MELANGE OU ASSOCIATION PHARMACEUTIQUE COMPRENANT COMME INGREDIENTS ACTIFS : (1) CEFTAZIDIME OU UN SEL DE CELUI-CI ET (2) AVIBACTAM OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/16/1109 - ZAVICEFTA - CEFTAZIDIME/AVIBACTAM |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.